Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssspta1623hrr

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

Roys

```
Web Page URLs for STN Seminar Schedule - N. America
NEWS
                 "Ask CAS" for self-help around the clock
NEWS
        Jul 12 BEILSTEIN enhanced with new display and select options,
NEWS
                 resulting in a closer connection to BABS
         Jul 30 BEILSTEIN on STN workshop to be held August 24 in conjunction
NEWS
                 with the 228th ACS National Meeting
        AUG 02 IFIPAT/IFIUDB/IFICDB reloaded with new search and display
NEWS
                 CAplus and CA patent records enhanced with European and Japan
        AUG 02
NEWS
                 Patent Office Classifications
         AUG 02 The Analysis Edition of STN Express with Discover!
NEWS
                 (Version 7.01 for Windows) now available
                 Pricing for the Save Answers for SciFinder Wizard within
         AUG 04
NEWS
     8
                 STN Express with Discover! will change September 1, 2004
                 BIOCOMMERCE: Changes and enhancements to content coverage
NEWS 9
        AUG 27
                 BIOTECHABS/BIOTECHDS: Two new display fields added for legal
        AUG 27
NEWS 10
                 status data from INPADOC
                 INPADOC: New family current-awareness alert (SDI) available
         SEP 01
NEWS 11
                 New pricing for the Save Answers for SciFinder Wizard within
NEWS 12
         SEP 01
                 STN Express with Discover!
         SEP 01 New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS 13
                 STN Patent Forum to be held October 13, 2004, in Iselin, NJ
         SEP 14
NEWS 14
                 STANDARDS will no longer be available on STN
         SEP 27
NEWS 15
NEWS 16 SEP 27 SWETSCAN will no longer be available on STN
NEWS EXPRESS JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT
              MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
              AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
              STN Operating Hours Plus Help Desk Availability
NEWS HOURS
              General Internet Information
NEWS INTER
              Welcome Banner and News Items
NEWS LOGIN
              Direct Dial and Telecommunication Network Access to STN
NEWS PHONE
              CAS World Wide Web Site (general information)
NEWS WWW
```

Welcome to STN International

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

=> file regis
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 11:46:32 ON 27 SEP 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 SEP 2004 HIGHEST RN 752189-88-1 DICTIONARY FILE UPDATES: 26 SEP 2004 HIGHEST RN 752189-88-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at: http://www.cas.org/ONLINE/DBSS/registryss.html

=> s 90780-53-3/rn L1 1 90780-53-3/RN

=> s 87042-40-8/rn

L2 1 87042-40-8/RN

=> s 90780-52-2/rn

L3 1 90780-52-2/RN

=> s 356041-27-5/rn

L4 1 356041-27-5/RN

=> s 90906-41-5/rn

L5 1 90906-41-5/RN

=> s 90780-51-1/rn

1 90780-51-1/RN

=> s 11 or 12 or 13 or 14 or 15 or 16

L7 6 L1 OR L2 OR L3 OR L4 OR L5 OR L6

=> s 17 full

L8 6 L1 OR L2 OR L3 OR L4 OR L5 OR L6

=> d 18 1-6 sub bib abs

L8 ANSWER 1 OF 6 REGISTRY COPYRIGHT 2004 ACS on STN

RN 356041-27-5 REGISTRY

CN 4,7,10,13,16,20-Docosahexaenoic acid, 19-hydroxy-, (4Z,7Z,10Z,13Z,16Z,20E)-(9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C22 H32 O3


SR CA

CA, CAPLUS, USPAT2, USPATFULL STN Files:

DT.CA CAplus document type: Patent

Roles from patents: BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)

Double bond geometry as shown.



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 2 REFERENCES IN FILE CA (1907 TO DATE)
- 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

139:79114 CA ΑN

Eicosapentaenoic acid and docosahexaenoic acid analogs induction of host TIdefense against bacteria

Serhan, Charles N.; Colgan, Sean P. IN

The Brigham and Women's Hospital, USA PA

PCT Int. Appl., 65 pp. SO

CODEN: PIXXD2

DTPatent

LΑ English

FAN CNT 2

FAN.	PATENT NO.				KII	KIND DATE			APPLICATION NO. DATE										
PI		, 2005055120				A2 20030703				WO 2002-US40586 20021218									
	WO	2003					20040226												
		W:	AE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	ВG,	BR,	BY,	ΒZ,	CA,	CH,	CN,	
			co.	CR.	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	
			GM.	HR.	HU.	ID.	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	ΚZ,	LC,	LK,	LR,	
			LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,	
			PL.	PT,	RO,	RU,	SD,	SE,	SG,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	ΤZ,	UA,	
			UG,	US,	UZ,	VN,	YU,	ZA,	ZM,	ZW,	AM,	ΑZ,	BY,	KG,	KZ,	MD,	RU,	ТJ,	TM
		RW:	GH.	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AT,	BE,	ВG,	
			CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	ΙE,	ΙT,	LU,	MC,	NL,	
			PT,	SE,	SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	
			MR,	NE,	SN,	TD,	TG												
	US 2003191184 US 2003195248			84	A1		2003	1009		U	S 20	02-3	2386	7	2002	1218			
				Α	1				U	S 20	02-3	2359	1	2002	1218				

PRAI US 2001-342138P 20011218


Methods to cause tissue, such as mucosal cells, to express increased amts. of bactericidal permeability increasing protein (BPI) are described. Various BPI inducing agents include eicosapentaenoic acid (EPA) analogs and docosahexaenoic acid (DHA) analogs. Thus, 18R-EPA analogs induced the

formation of BPI. Results demonstrated quant. PCR for BPI in epithelial cells.

```
ΑN
     135:190408 CA
     Aspirin-triggered lipid mediators
TΙ
     Serhan, Charles N.; Clish, Clary B.
IN
     The Brigham and Women's Hospital, Inc., USA
PΑ
     PCT Int. Appl., 74 pp.
SO
     CODEN: PIXXD2
DT
     Patent
LA
     English
FAN.CNT 1
                      KIND
                            DATE
                                            APPLICATION NO.
                                                             DATE
     PATENT NO.
                       _ - - -
                                            WO 2001-US5196
                                                             20010216
                             20010823
PΙ
     WO 2001060778
                       A2
                            20021024
                       C2
     WO 2001060778
                      ∖A3
                           20030116
     WO 2001060778
             AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
             ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                            US 2001-785866
                             20020509
     US 2002055538
                       Α1
                             20031230
                       B2
     US 6670396
                                            EP 2001-910912
                             20030402
                                                             20010216
     EP 1296923
                       A2
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                            JP 2001-559832
                                                             20010216
     JP 2003525880
                        T2
                             20030902
                                            US 2003-663061
                                                             20030912
     US 2004059144
                       A1
                             20040325
                      20000216
PRAI US 2000-183078P
                      20001006
     US 2000-238814P
                       20010216
     US 2001-785866
                       20010216
     WO 2001-US5196
     Aspirin triggered lipid mediators are disclosed which are useful for the
AB
     treatment or prevention of inflammation associated with various diseases,
     including ischemia. The present invention provides that inflammatory
     exudates from mice treated with \omega\text{--3} PUFA and aspirin generate a
     novel array of bioactive lipid signals. Human endothelial cells with
     upregulated COX-2 treated with aspirin converted C20:5 w-3 to 18R-HEPE and
     15R-HEPE. Each was used by polymorphonuclear leukocytes to generate sep.
     classes of novel trihydroxy-containing mediators, including 15R-lipoxin and
     5,12,18R-triHEPE. These compds. were potent inhibitors of human
     polymorphonuclear leukocyte transendothelial migration and infiltration in
     vivo.
     ANSWER 2 OF 6 REGISTRY COPYRIGHT 2004 ACS on STN
L8
     90906-41-5 REGISTRY
RN
     4,7,10,13,16,18-Docosahexaenoic acid, 20-hydroxy-, (4Z,7Z,10Z,13Z,16Z,18E)-
CN
             (CA INDEX NAME)
       (9CI)
OTHER CA INDEX NAMES:
     4,7,10,13,16,18-Docosahexaenoic acid, 20-hydroxy-, (E,Z,Z,Z,Z,Z)-
CN
     STEREOSEARCH
FS
     131391-58-7
DR
     C22 H32 O3
MF
                   CA, CAPLUS, CHEMCATS, CSCHEM, USPAT7, USPATFULL
     STN Files:
LC
DT.CA CAplus document type: Journal; Patent
```

RL.NP Roles from non-patents: ANST (Analytical study); FORM (Formation, nonpreparative); PREP (Preparation)

Double bond geometry as shown.



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 6 REFERENCES IN FILE CA (1907 TO DATE)
- 6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

US 2003191184

US 2003195248

139:79114 CA ΔN Eicosapentaenoic acid and docosahexaenoic acid analogs induction of host TI defense against bacteria Serhan, Charles N.; Colgan, Sean P. IN The Brigham and Women's Hospital, USA PA PCT Int. Appl., 65 pp. SO CODEN: PIXXD2 DTPatent English LAFAN.CNT 2 KIND APPLICATION NO. DATE DATE PATENT NO. WO 2003053423 A2 20030703 WO 2002-US40586 20021218 PΙ WO 2003053423 A3 20040226 W: AE, AG, AL, AM, AT, AU, AZ/BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CO, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HD, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-342138P 20011218

AB Methods to cause tissue, such as mucosal cells, to express increased amts. of bactericidal permeability increasing protein (BPI) are described. Various BPI inducing agents include eicosapentaenoic acid (EPA) analogs and docosahexaenoic acid (DHA) analogs. Thus, 18R-EPA analogs induced the formation of BPI. Results demonstrated quant. PCR for BPI in epithelial

20031009

20031016

Α1

Αl

US 2002-323867

US 2002-323591

20021218

20021218

```
10663061
```

cells.

```
REFERENCE 2
```

```
135:190408 CA
AN
    Aspirin-triggered lipid mediators
TI
    Serhan, Charles N.; Clish, Clary B.
IN
     The Brigham and Women's Hospital, Inc., USA
PA
SO
     PCT Int. Appl., 74 pp.
     CODEN: PIXXD2
DT
    Patent
    English
LA
FAN.CNT 1
     PATENT NO.
                    KIND DATE
                                        APPLICATION NO. DATE
                                          _____
     ______
                           20010823
                                         WO 2001-US5196 20010216
PΙ
    WO 2001060778 A2
    WO 2001060778
                    C2
                           20021024
                    A3
                           20030116
     WO 2001060778
            AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
            HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
            LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
            SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
            ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 2002055538
                     A1
                           20020509
                                         US 2001-785866
                                                          20010216
                           20031230
    US 6670396
                      B2
                           20030402
                                          EP 2001-910912
                                                           20010216
     EP 1296923
                      A2
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                        JP 2001-559832
                                                           20010216
     JP 2003525880
                      T2
                           20030902
                                         US 2003-663061
    US 2004059144
                           20040325
                                                          20030912
                      A1
PRAI US 2000-183078P 20000216
     US 2000-238814P 20001006
     US 2001-785866
                     20010216
     WO 2001-US5196
                    20010216
     Aspirin triggered lipid mediators are disclosed which are useful for the
AB
     treatment or prevention of inflammation associated with various diseases,
     including ischemia. The present invention provides that inflammatory
     exudates from mice treated with \omega-3 PUFA and aspirin generate a
     novel array of bioactive lipid signals. Human endothelial cells with
     upregulated COX-2 treated with aspirin converted C20:5 w-3 to 18R-HEPE and
     15R-HEPE. Each was used by polymorphonuclear leukocytes to generate sep.
     classes of novel trihydroxy-containing mediators, including 15R-lipoxin and
     5,12,18R-triHEPE. These compds. were potent inhibitors of human
     polymorphonuclear leukocyte transendothelial migration and infiltration in
     vivo.
```

- AN 120:265249 CA
- TI High-performance liquid chromatography-thermospray mass spectrometry of epoxy polyunsaturated fatty acids and epoxyhydroxy polyunsaturated fatty acids from an incubation mixture of rat tissue homogenate
- AU Yamane, Mototeru; Abe, Akihisa; Yamane, Sayoko
- CS Dep. Biochem., Tokyo Med. Coll., Tokyo, Japan
- SO Journal of Chromatography, B: Biomedical Sciences and Applications (1994), 652(2), 123-36
 CODEN: JCBBEP; ISSN: 1387-2273
- DT Journal

LA English

AB A method for the anal. of epoxy polyunsatd. fatty acids (EpPUFAs) and epoxyhydroxy polyunsatd. fatty acids (EpHPUFAs) in rat tissue homogenate, with homo- γ -linolenic acid (20:3,n-6), arachidonic acid (20:4,n-6), eicosapentaenoic acid (20:5,n-3) or docosahexaenoic acid (22:6,n-3) as a substrate, was developed. Extraction with dichloromethane at pH 4-5 and concentration

in the presence of pyridine were performed. Spectral anal. of chromatograms obtained with HPLC-thermospray mass spectrometry showed the presence of EpPUFAs, EpHPUFAs and dihydroxy metabolites (DiHPUFAs) of EpPUFAs corresponding to each precursor fatty acid. On a selected-ion monitoring chromatogram, many EpPUFAs, EpHPUFAs and DiHPUFAs in an extract from an incubation mixture of each precursor fatty acid in aged rat tissue homogenate were detected simultaneously within 70 min. EpPUFAs and DiHPUFAs derived from 20:3 (n-6) or 20:5 (n-3) were detected in significant amts. From these results, a highly active cytochrome P 450 system or nonenzymic oxidative reactions in aged rat tissue homogenate were suggested.

REFERENCE 4

AN 119:265901 CA

- Facile preparation and structural determination of monohydroxy derivatives of docosahexaenoic acid (HDoHE) by α -tocopherol-directed autoxidation
- AU Reynaud, Denis; Thickitt, Christopher P.; Pace-Asciak, Cecil R.
- CS Res. Inst., Hosp. Sick Child., Toronto, ON, M5G 1X8, Can.
- SO Analytical Biochemistry (1993), 214(1), 165-70 CODEN: ANBCA2; ISSN: 0003-2697
- DT Journal
- LA English
- Polyunsatd. fatty acids are oxidized through both enzymic and nonenzymic AΒ reactions into hydroxy derivs. With increasing interest in dietary manipulations through ingestion of the highly unsatd. fish oil fatty acids, eicosapentaenoic acid and docosahexaenoic acid (DHA), methods to measure their metabolism are required. In this study the authors report the simple and expedient α -tocopherol-directed autoxidative preparation of a series of monohydroxy derivs. of DHA to provide a relatively homogeneous hydroxylation along each of the double bonds of the fatty substrate. Products were purified by high-performance liquid chromatog. (HPLC) and their structures elucidated by the characteristic fragmentation pattern of the hydrogenated Me ester trimethylsilyl ether derivs. by gas chromatog.-mass spectrometry. Nine products were isolated in 20.2% yield overall, ranging from 1.55 to 4.14% yield of isolated compound These were identified as 7, 8, 10, 11, 13, 14, 16, 17, and 20-HDOHES (monohydroxydocosahexaenoic acids). Two of these products (14- and 17-HDOHE) could not be separated under the HPLC conditions used but were clearly distinguished using selected ion chromatog. by their distinct mass spectral fragmentation. This method is highly suitable for the generation of stds. to investigate the metabolism of DHA in tissues.

- AN 114:39806 CA
- TI Stereochemical analysis of hydroxylated docosahexaenoates produced by human platelets and rat brain homogenate
- AU Kim, H. Y.; Karanian, J. W.; Shingu, T.; Salem, N., Jr.
- CS Sect. Anal. Chem., NIAAA, Bethesda, MD, 20892, USA
- SO Prostaglandins (1990), 40(5), 473-90 CODEN: PRGLBA; ISSN: 0090-6980
- DT Journal
- LA English

M

The stereochem. configuration of hydroxylated products of docosahexaenoic acid $(22:6\omega3)$ formed by human platelets and rat brain homogenate were characterized for the first time. Chiral phase HPLC was employed along with autoxidized $22:6\omega3$ as reference material. The 14- and 11-hydroy $22:6\omega3$ (HDHE) products produced by human platelets were in the S configuration. Rat brain homogenate produced all of the 10 possible positional isomers when incubated with $22:6\omega3$. Their retention behavior on the reversed and chiral phase HPLC columns and GC/MS/EI anal. indicated that they were 20-, 17-, 16-, 14-, 13-, 11-, 10-, 8-, 7- and 4-HDHE. However, stereochem. anal. revealed that each positional isomer was a racemic mixture, suggesting that these were not formed by lipoxygenation but mainly by peroxidn. process.

REFERENCE 6

AN 101:35331 CA

TI Autooxidation of docosahexaenoic acid: analysis of ten isomers of hydroxydocosahexaenoate

AU VanRollins, Mike; Murphy, Robert C.

CS Health Sci. Cent., Univ. Colorado, Denver, CO, 80262, USA

SO Journal of Lipid Research (1984), 25(5), 507-17 CODEN: JLPRAW; ISSN: 0022-2275

DT Journal

LA English

Docosahexaenoic acid, an n-3 essential fatty acid, is enzymically converted by platelets, basophils, and liver microsomes into metabolites containing conjugated diens with allylic hydroxyl groups. To help identify these metabolites, stds. were prepared by autoxidn. of docosahexaenoic acid. After isolation by reverse phase and normal phase high-performance chromatog. (HPLC), 10 hydroxy isomers of docosahexaenoic acid were identified by capillary gas-liquid chromatog., UV spectroscopy, and mass spectrometry. From these studies and reported elution orders for similar metabolites derived from linoleic, linolenic, and arachidonic acids, 2 basic HPLC elution patterns became apparent. Under reverse phase chromatog. conditions, the distance of the trans-double bond from the carboxyl group was the critical parameter in determining the elution order.

Under

silicic acid chromatog. conditions, the distance of the hydroxyl from the carbomethoxy group seemed to determine the elution order. The dramatic difference in selectivity between reverse and normal phase HPLC of the hydroxy acids provides critical information useful for identifying endogenous metabolites.

L8 ANSWER 3 OF 6 REGISTRY COPYRIGHT 2004 ACS on STN

RN 90780-53-3 REGISTRY

CN 4,7,10,14,16,19-Docosahexaenoic acid, 13-hydroxy-, (4Z,7Z,10Z,14E,16Z,19Z)-(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 4,7,10,14,16,19-Docosahexaenoic acid, 13-hydroxy-, (E,Z,Z,Z,Z,Z)-

FS STEREOSEARCH

DR 131391-60-1

MF C22 H32 O3


LC STN Files: CA, CAPLUS, CHEMCATS, CSCHEM, USPAT7, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PRP (Properties)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 8 REFERENCES IN FILE CA (1907 TO DATE)
- 8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

- AN 139:177077 CA
- TI Novel Docosatrienes and 17S-Resolvins Generated from Docosahexaenoic Acid in Murine Brain, Human Blood, and Glial Cells
- AU Hong, Song; Gronert, Karsten; Devchand, Pallavi R.; Moussignac, Rose-Laure; Serhan, Charles N.
- CS Perioperative and Pain Medicine, Department of Anesthesiology, Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital and Harvard Medical School, Roston, MA, 02115, USA
- SO Journal of Biological Chemistry (2003), 278(17), 14677-14687 CODEN: JBCHA3; ISSN: 0021-9258
- PB American Society for Biochemistry and Molecular Biology
- DT Journal
- LA English
- AB 4 Docosahexaenoic acid (DHA, C22:6) is highly enriched in brain, synapses, and retina and is a major ω -3 fatty acid. Deficiencies in this essential fatty acid are reportedly associated with neuronal function, cancer, and inflammation. Here, using new lipid analyses employing high performance liquid chromatog. coupled with a photodiode-array detector and a tandem mass spectrometer, a novel series of endogenous mediators was identified in blood, leukocytes, brain, and glial cells as 17S-hydroxy-containing docosanoids denoted as docosatrienes (the main bioactive member of the series was 10,17S-docosatriene) and 17S series resolvins. These novel mediators were biosynthesized via epoxide-containing intermediates and proved potent (pico- to nanomolar range) regulators of both leukocytes reducing infiltration in vivo and glial cells blocking their cytokine production These results indicate that DHA is the precursor to potent protective mediators generated via enzymic oxygenations to novel docosatrienes and 17S series resolvins that each regulate events of interest in inflammation and resolution
- RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

- AN 139:79114 CA
- TI Eicosapentaenoic acid and docosahexaenoic acid analogs induction of host defense against bacteria
- IN Serhan, Charles N.; Colgan, Sean P.
- PA The Brigham and Women's Hospital, USA
- SO PCT Int. Appl., 65 pp. CODEN: PIXXD2
- DT Patent
- LA English
- FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE		
PI	WO 2003053423	A2	20030703	WO 2002-US40586	20021218		
	WO 2003053423	A3	20040226				

```
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SL, SK, TR, BF, BI, CF, CG, CI, CM, GA, GN, GO, GW, MI,
                PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
                MR, NE, SN, TD, TG
      US 2003191184
                            A1
                                   20031009
                                                      US 2002-323867
                                                                            20021218
      US 2003195248
                            A1
                                   20031016
                                                      US 2002-323591
                                                                            20021218
PRAI US 2001-342138P 20011218
      Methods to cause tissue, such as mucosal cells, to express increased amts.
      of bactericidal permeability increasing protein (BPI) are described.
      Various BPI inducing agents include eicosapentaenoic acid (EPA) analogs
      and docosahexaenoic acid (DHA) analogs. Thus, 18R-EPA analogs induced the
      formation of BPI. Results demonstrated quant. PCR for BPI in epithelial
      cells.
REFERENCE 3
AN
      135:190408 CA
TI
      Aspirin-triggered lipid mediators
IN
      Serhan, Charles N., Clish, Clary B.
      The Brigham and Women's Hospital, Inc., USA
PA
SO
      PCT Int. Appl., 74 pp.
      CODEN: PIXXD2
DT
      Patent
      English
LA
FAN.CNT 1
      PATENT NO.
                           KIND/
                                   DATE
                                                      APPLICATION NO.
                                                                            DATE
      WO 2001060778
                            A/2
                                   20010823
                                                      WO 2001-US5196
PΙ
                                                                            20010216
      WO 2001060778
                             ¢2
                                   20021024
      WO 2001060778
                            A3 ;
                                   20030116
                AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
                CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
                LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
                SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
                ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
           RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
                DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
                BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
      US 2002055538
                                   20020509
                                                     US 2001-785866
                            A1
                                                                           20010216
      US 6670396
                            B2
                                   20031230
      EP 1296923
                            A2
                                   20030402
                                                      EP 2001-910912
                                                                           20010216
               AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
                IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
      JP 2003525880
                            T2
                                   20030902
                                                      JP 2001-559832
                                                                           20010216
      US 2004059144
                                                      US 2003-663061
                                   20040325
                                                                           20030912
                            A1
PRAI US 2000-183078P
                           20000216
      US 2000-238814P
                           20001006
      US 2001-785866
                           20010216
      WO 2001-US5196
                           20010216
      Aspirin triggered lipid mediators are disclosed which are useful for the
AΒ
      treatment or prevention of inflammation associated with various diseases,
      including ischemia. The present invention provides that inflammatory
      exudates from mice treated with \omega-3 PUFA and aspirin generate a
      novel array of bioactive lipid signals. Human endothelial cells with
      upregulated COX-2 treated with aspirin converted C20:5 w-3 to 18R-HEPE and
```

15R-HEPE. Each was used by polymorphonuclear leukocytes to generate sep. classes of novel trihydroxy-containing mediators, including 15R-lipoxin and 5,12,18R-triHEPE. These compds. were potent inhibitors of human polymorphonuclear leukocyte transendothelial migration and infiltration in vivo.

REFERENCE 4

- AN121:78737 CA
- Polyunsaturated-fatty-acid oxidation in Hydra: regioselectivity, ΤI substrate-dependent enantioselectivity and possible biological role
- Di Marzo, Vincenzo; Gianfrani, Carmen; De Petrocellis, Luciano; Milone, AU Alfredo; Cimino, Guido
- Ist. Chim. Mol. Interesse Biol., CNR, Arco Felice, 80072, Italy CS
- Biochemical Journal (1994), 300(2), 501-7 SO CODEN: BIJOAK; ISSN: 0264-6021
- DTJournal
- English LA
- A novel and abundant lipoxygenase-like activity converting AB cis-eicosa-5,8,11,14-tetraenoic acid (arachidonic acid) into (11R)-hydroxyeicosatetraenoic acid has been recently described in homogenates of the freshwater hydrozoan Hydra vulgaris. In this study, other substrates for this enzyme were selected from the polyunsatd. fatty acids (PUFAs) present in H. vulgaris, and the chemical natures of the hydroperoxy and hydroxy derivs. produced, as well as the activity of some of the latter on hydroid tentacle regeneration, were investigated. The highest conversion among C20 fatty acids was observed for arachidonic acid, and among C18 fatty acids for cis-octadeca-9,12,15- and cis-octadeca-6,9,12-trienoic (α - and γ -linolenic) acids. Cis double bonds on the 10th C atom from the aliphatic end of the substrate (e.g. C-9, C-11, and C-13 resp. in C18, C20, and C22 PUFAs) were regiospecifically peroxidized. Conversely, trans-octadeca-9,12-dienoic (linelaidic) acid was not a substrate for lipoxygenase activity. Enantioselectivity of lipoxygenation depended on the degree of unsatn. of the substrate, with the amount of the R enantiomer increasing when passing, for example, from cis-eicosa-11,14-dienoic to cis-eicosa-5,8,11,14,17pentaenoic acid. Regiospecific formation of keto acids was observed only when incubating C18 PUFAs. Com. available hydroxyacids corresponding to the reaction products of some of the most abundant H. vulgaris PUFAs were tested for effects on Hydra tentacle regeneration. An enhancement of average tentacle number, in a fashion depending on the stereochem. and on the number of double bonds, was found for 2 compds., thus suggesting for the 11-lipoxygenase-like enzyme a role in the production of metabolites potentially active in the control of hydroid regenerative processes.

- ΑN 119:265901 CA
- Facile preparation and structural determination of monohydroxy derivatives TТ of docosahexaenoic acid (HDoHE) by α -tocopherol-directed autoxidation
- Reynaud, Denis; Thickitt, Christopher P.; Pace-Asciak, Cecil R. ΑU
- Res. Inst., Hosp. Sick Child., Toronto, ON, M5G 1X8, Can. CS
- Analytical Biochemistry (1993), 214(1), 165-70 SO CODEN: ANBCA2; ISSN: 0003-2697
- DT Journal
- English LA
- Polyunsatd. fatty acids are oxidized through both enzymic and nonenzymic AΒ reactions into hydroxy derivs. With increasing interest in dietary manipulations through ingestion of the highly unsatd. fish oil fatty acids, eicosapentaenoic acid and docosahexaenoic acid (DHA), methods to measure their metabolism are required. In this study the authors report the

simple and expedient α -tocopherol-directed autoxidative preparation of a series of monohydroxy derivs. of DHA to provide a relatively homogeneous hydroxylation along each of the double bonds of the fatty substrate. Products were purified by high-performance liquid chromatog. (HPLC) and their structures elucidated by the characteristic fragmentation pattern of the hydrogenated Me ester trimethylsilyl ether derivs. by gas chromatog.-mass spectrometry. Nine products were isolated in 20.2% yield overall, ranging from 1.55 to 4.14% yield of isolated compound. These were identified as 7, 8, 10, 11, 13, 14, 16, 17, and 20-HDoHEs (monohydroxydocosahexaenoic acids). Two of these products (14- and 17-HDoHE) could not be separated under the HPLC conditions used but were clearly distinguished using selected ion chromatog. by their distinct mass spectral fragmentation. This method is highly suitable for the generation of stds. to investigate the metabolism of DHA in tissues.

REFERENCE 6

- AN 114:39806 CA
- TI Stereochemical analysis of hydroxylated docosahexaenoates produced by human platelets and rat brain homogenate
- AU Kim, H. Y.; Karanian, J. W.; Shingu, T.; Salem, N., Jr.
- CS Sect. Anal. Chem., NIAAA, Bethesda, MD, 20892, USA
- SO Prostaglandins (1990), 40(5), 473-90 CODEN: PRGLBA; ISSN: 0090-6980
- DT Journal
- LA English
- The stereochem. configuration of hydroxylated products of docosahexaenoic acid (22:6\omega3) formed by human platelets and rat brain homogenate were characterized for the first time. Chiral phase HPLC was employed along with autoxidized 22:6\omega3 as reference material. The 14- and 11-hydroy 22:6\omega3 (HDHE) products produced by human platelets were in the S configuration. Rat brain homogenate produced all of the 10 possible positional isomers when incubated with 22:6\omega3. Their retention behavior on the reversed and chiral phase HPLC columns and GC/MS/EI anal. indicated that they were 20-, 17-, 16-, 14-, 13-, 11-, 10-, 8-, 7- and 4-HDHE. However, stereochem. anal. revealed that each positional isomer was a racemic mixture, suggesting that these were not formed by lipoxygenation but mainly by peroxidn. process.

REFERENCE 7

- AN 101:35331 CA
- TI Autooxidation of docosahexaenoic acid: analysis of ten isomers of hydroxydocosahexaenoate
- AU VanRollins, Mike; Murphy, Robert C.
- CS Health Sci. Cent., Univ. Colorado, Denver, CO, 80262, USA
- SO Journal of Lipid Research (1984), 25(5), 507-17 CODEN: JLPRAW; ISSN: 0022-2275
- DT Journal
- LA English
- Docosahexaenoic acid, an n-3 essential fatty acid, is enzymically converted by platelets, basophils, and liver microsomes into metabolites containing conjugated diens with allylic hydroxyl groups. To help identify these metabolites, stds. were prepared by autoxidn. of docosahexaenoic acid. After isolation by reverse phase and normal phase high-performance chromatog. (HPLC), 10 hydroxy isomers of docosahexaenoic acid were identified by capillary gas-liquid chromatog., UV spectroscopy, and mass spectrometry. From these studies and reported elution orders for similar metabolites derived from linoleic, linolenic, and arachidonic acids, 2 basic HPLC elution patterns became apparent. Under reverse phase chromatog. conditions, the distance of the trans-double bond from the carboxyl group was the critical parameter in determining the elution order.

Under

silicic acid chromatog. conditions, the distance of the hydroxyl from the carbomethoxy group seemed to determine the elution order. The dramatic difference in selectivity between reverse and normal phase HPLC of the hydroxy acids provides critical information useful for identifying endogenous metabolites.

REFERENCE 8

AN 101:19194 CA

TI Oxidation of docosahexaenoic acid by rat liver microsomes

AU VanRollins, Mike; Baker, Rodney C.; Sprecher, Howard W.; Murphy, Robert C.

CS Health Sci. Cent., Univ. Colorado, Denver, CO, 80262, USA

SO Journal of Biological Chemistry (1984), 259(9), 5776-83 CODEN: JBCHA3; ISSN: 0021-9258

DT Journal

LA English

[1-14C]docosahexaenoic acid (n-3) was incubated at 37° for 30 min AB in the presence of rat liver microsomes and 1 mM NADPH. The products were isolated by using organic solvent extns., and reverse phase and normal phase HPLC. Isolates were identified by UV spectroscopy, capillary gas-liquid chromatog., and gas chromatog.-mass spectrometer. The major metabolites were: 19,20-, 16,17-, 13,14-, 10,11-, and 7,8-dihydroxydocosapentaenoic acids, 22-hydroxydocosahexaenoic acid, and 21-hydroxydocosahexaenoic acid. The minor metabolites were 17-hydroxy-4,7,10,13,15,19-, 16-hydroxy-4,7,10,17,19-, 14-hydroxy-4,7,10,12,-16,19-, 13-hydroxy-4,7,10,14,16,19-, 11-hydroxy-4,7,9,13,16,19-, 10-hydroxy-4,7,11,13,16,19-,8-hydroxy-4,6,10,13,16,19-, and 7-hydroxy-4,8,10,13,16,19-docosahexaenoic acids. These metabolites of docosahexaenoic acid resulted from 4 distinct classes of oxidation, ω -hydroxylations, (ω -1)-hydroxylations, epoxidns., and lipoxygenase-like hydroxylations. The similarity of these product profiles to those reported for comparable microsomal incubations with other essential fatty acids suggest that microsome cytochrome P 450 monooxygenases were involved.

L8 ANSWER 4 OF 6 REGISTRY COPYRIGHT 2004 ACS on STN

RN 90780-52-2 REGISTRY

CN 4,7,10,13,15,19-Docosahexaenoic acid, 17-hydroxy-, (4Z,7Z,10Z,13Z,15E,19Z)-(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 4,7,10,13,15,19-Docosahexaenoic acid, 17-hydroxy-, (E,Z,Z,Z,Z,Z)-

FS STEREOSEARCH

DR 131485-67-1

MF C22 H32 O3

LC STN Files: CA, CANCERLIT, CAPLUS, CHEMCATS, CSCHEM, MEDLINE, TOXCENTER, USPAT2, USPATFULL

DT.CA CAplus document type: Conference; Journal; Patent

RL.P Roles from patents: BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process)

Double bond geometry as shown.

```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**
```

17 REFERENCES IN FILE CA (1907 TO DATE) 17 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

```
139:79114 CA
AN
```

- ΤI Eicosapentaenoic acid and docosahexaenoic acid analogs induction of host defense against bacteria
- Serhan, Charles N.; Colgan, Sean P. IN
- PA The Brigham and Women's Hospital, USA
- SO PCT Int. Appl., 65 pp. CODEN: PIXXD2
- Patent DT
- LΑ English

FAN.	CNT	2																			
	PATENT NO.					KIND DATE			DATE APPLICATION NO.							DATE					
ΡI	WO	2003	0534	23	A:	2	20030703			WO 2002-US40586 20021218											
	WO	2003	0534	23	A.	A3 20040226															
		W:	ΑE,	AG,	AL,	AM,	ΑT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,			
			CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,			
			GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	ΚZ,	LC,	LK,	LR,			
			LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,			
			PL,	PT,	RO,	RU,	SD,	SE,	SG,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	${f T} Z$,	UA,			
			ŪĠ,	US,	UΖ,	VN,	YU,	ZA,	ZM,	ZW,	AM,	ΑZ,	BY,	KG,	ΚZ,	MD,	RU,	ТJ,	TM		
		RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	ΑT,	ΒE,	BG,			
			CH,	CY,	CZ,	DΕ,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,			
			PT,	SE,	SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,			
			MR,	ΝE,	SN,	TD,	TG														
	US	2003	1911	84	A:	1	2003	1009		U	S 20	02-3	2386′	7	2002	1218					
	US	JS 2003195248			A.	1.	2003	1016		US 2002-323591 20021218											

PRAI US 2001-342138P 20011218

Methods to cause tissue, such as mucosal cells, to express increased amts. of bactericidal permeability increasing protein (BPI) are described. Various BPI inducing agents include eicosapentaenoic acid (EPA) analogs and docosahexaenoic acid (DHA) analogs. Thus, 18R-EPA analogs induced the formation of BPI. Results demonstrated quant. PCR for BPI in epithelial cells.

- AN 136:147175 CA
- Monohydroxylated fatty acid content in peripheral blood mononuclear cells TТ and immune status of people at long times after the Chernobyl accident
- Chumak, Anatoliy; Thevenon, Chantal; Gulaya, Nadya; Guichardant, Michel; ΑU Margitich, Victor; Bazyka, Dimitry; Kovalenko, Alexander; Lagarde, Michel; Prigent, Annie-France
- CS INSERM, Biochimie et Pharmacologie INSA Lyon, Villeurbanne, 69621, Fr.
- Radiation Research (2001), 156(5, Pt. 1), 476-487 SO CODEN: RAREAE; ISSN: 0033-7587
- Radiation Research Society PB
- DT Journal
- LΑ English
- AB The monohydroxylated fatty acid content of peripheral blood mononuclear cells from 23 cleanup workers and 16 unexposed individuals was studied in relation to their immune status after the Chernobyl accident. Men with absorbed doses below 0.32 Gy showed higher levels of free and esterified 12-hydroxyeicosatetraenoic acid (12-HETE) than unexposed men, whereas 15-HETE and the 17-hydroxy derivative of C22 fatty acid (17-OH 22), either

free or esterified in phospholipids, were increased in a dose-dependent manner. The percentage of CD4-pos. cells was also increased significantly in heavily irradiated men, whereas the percentage of CD8-pos. cells tended to decrease with dose. Furthermore, the absolute count of CD4-pos. cells was correlated pos. with the amount of esterified 15-HETE in the phospholipid fraction of the mononuclear cells and with the total 15-HETE. These results show for the first time that the accumulation of autoxidized/lipoxygenase products of polyunsatd. fatty acids in the mononuclear cells of irradiated individuals was associated with immune imbalance. This may be the basis for certain late effects of radiation such as autoimmune disorders, somatic and neoplastic diseases, and early aging.

RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

REFERENCE 3

ΔN

135:190408 CA

```
Aspirin-triggered lipid mediators
TI
     Serhan, Charles N.; Clish, Clary B.
IN
     The Brigham and Women's Hospital, Inc., USA
PΑ
     PCT Int. Appl., 74 pp.
SO
     CODEN: PIXXD2
DT
     Patent
    English
LΑ
FAN.CNT 1
                                          APPLICATION NO. DATE
                     KIND DATE
     PATENT NO.
                                          ______
                                          WO 2001-US5196
                                                           20010216
     WO 2001060778
                     A2
                           20010823
PΙ
     WO 2001060778
                     C2
                            20021024
     WO 2001060778
                    A3
                            20030116
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
             ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                          US 2001-785866
                            20020509
     US 2002055538
                      A1
                            20031230
     US 6670396
                      B2
                            20030402
                                          EP 2001-910912
                                                            20010216
     EP 1296923
                      A2
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                          JP 2001-559832
                                                            20010216
     JP 2003525880
                      T2
                            20030902
                                          US 2003-663061
                                                            20030912
     US 2004059144
                      A1
                            20040325
PRAI US 2000-183078P
                      20000216
                      20001006
     US 2000-238814P
                      20010216
     US 2001-785866
     WO 2001-US5196
                      20010216
```

Aspirin triggered lipid mediators are disclosed which are useful for the treatment or prevention of inflammation associated with various diseases, including ischemia. The present invention provides that inflammatory exudates from mice treated with ω-3 PUFA and aspirin generate a novel array of bioactive lipid signals. Human endothelial cells with upregulated COX-2 treated with aspirin converted C20:5 w-3 to 18R-HEPE and 15R-HEPE. Each was used by polymorphonuclear leukocytes to generate sep. classes of novel trihydroxy-containing mediators, including 15R-lipoxin and 5,12,18R-triHEPE. These compds. were potent inhibitors of human polymorphonuclear leukocyte transendothelial migration and infiltration in vivo.

REFERENCE 4

AN 129:202364 CA

TI N-3 fatty acid deficiency in the rat pineal gland: effects on phospholipid molecular species composition and endogenous levels of melatonin and lipoxygenase products

AU Zhang, Hongjian; Hamilton, Jillonne H.; Salem, Norman, Jr.; Kim, Hee-Yong

CS Section of Mass Spectrometry, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD, 20852, USA

SO Journal of Lipid Research (1998), 39(7), 1397-1403 CODEN: JLPRAW; ISSN: 0022-2275

PB Lipid Research, Inc.

DT Journal

LA English

N-3 essential fatty acid deficiency affects a number of biol. and physiol. AB processes. In this study, the authors investigated the effect of n-3 essential fatty acid status on two key pineal biochem. functions, melatonin production and lipoxygenation, using pineal glands from rats given an n-3-adequate or n-3-deficient diet. The pineal total lipid profile and phospholipid mol. species distribution altered by n-3 deficiency were evaluated in parallel. In pineal glands from n-3-deficient rats, an 87% reduction of 22:6n-3 (docosahexaenoic acid) was observed, and this decrease was accompanied by increases in 22:4n-6 (docosatetraenoic acid, 3-fold), 22:5n-6 (docosapentaenoic acid, 12-fold), and 20:4n-6 (arachidonic acid, 48%). The significant decrease of 22:6n-3 containing species in phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylserine (PS) was also evident. These decreases in 22:6n-3 containing PL species were compensated by substantial accumulations of 22:4n-6 or 22:5n-6 and slight increases in 20:4n-6 containing PL species in PC and PE. In PS, however, the accumulation of n-6 species was not adequate to compensate for the loss of 22:6n-3 species. N-3 deficiency significantly reduced non-esterified 20:4n-6 and 22:6n-3 levels in pineals (25% and 65%, resp.). Concomitantly, the endogenous 12-HETE level decreased by 35% in deficient pineals. In contrast, n-3 deficiency led to a more than 60% increase in the daytime pineal melatonin level. In conclusion, n-3 fatty acid deficiency not only has profound effects on pineal lipid profiles but also on pineal biochem. activities. These results suggest that n-3 fatty acids may play a critical role in regulating pineal function.

RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

REFERENCE 5

AN 124:26230 CA

TI Biosynthesis of docosanoids by human platelet: Cardiovascular properties

AU Karanian, John W.; Kim, Hee Yong; Salem, Norman Jr.

CS Laboratory Membrane Biochemistry and Biophysics, DICBR/NIAAA, Rockville, MD, 20852, USA

Cardiovascular Disease 2: Cellular and Molecular Mechanisms, Prevention, and Treatment, [Proceedings of the Washington International Spring Symposium], 14th, Washington, D. C., June 6-10, 1994 (1995), Meeting Date 1994, 269-77. Editor(s): Gallo, Linda L. Publisher: Plenum, New York, N. Y.

CODEN: 61ZNA9

DT Conference

LA English

AB A reliable purification and quantification method is presented that was used to characterize the metabolism and production of the hydroxylated derivs. Of 22:5n3,

22:6n3, 22:5n5 and 22:5n6 from mammalian platelets. Their biol. properties in platelet and vascular smooth muscle cell function is

discussed.

REFERENCE 6

- AN 121:277471 CA
- TI Inhibitory effects of n-6 and n-3 hydroxy fatty acids on thromboxane (U46619)-induced smooth muscle contraction
- AU Karanian, J. W.; Kim, H. Y.; Salem, Norman, Jr.
- CS Lab. Membrane Biochem. and Biophysics, Natl. Inst. Alcohol Abuse and Alcoholism, Bethesda, MD, USA
- SO Journal of Pharmacology and Experimental Therapeutics (1994), 270(3), 1105-9
 CODEN: JPETAB; ISSN: 0022-3565
- DT Journal
- LA English
- AB Mammalian platelets are capable of enzymically producing a number of n-6 and n-3 hydroxy fatty acids. Human platelet suspensions produce two major docosahexaenoic acid (22:6n3) metabolites, namely, 11-OH- and 14-OH-22:6n3. The hydroxy fatty acids which were formed by human platelets and purified by high performance liquid chromatog. specifically antagonize the contractile effects of a thromboxane mimetic, U46619, in airway, visceral and, especially, in the vascular smooth muscle prepns. studied.

The efficacy of OH-22:6n3 (IC25 = 1.1 μ M) was compared to other n-6 and n-3 hydroxy fatty acids in the rat aortic ring preparation. The OH-22:6n3 was significantly more potent with the exception of OH-22:5n3. The rank order of their potency was 14-OH-22:5n3 \geq 14-OH-22:6n3 \geq 17-OH-22:6n3 \geq 11-OH-22:5n3 \geq 12-OH-20:5n3 \geq 12-OH-20:4n6 \geq 14-OH-22:5n6 > 13-OH-18:2n6 > 14-OH-22:5n5. Antagonism of thromboxane effects may be an important aspect of the biol. function of 22-carbon n-3 hydroxylated fatty acids in the platelet-vascular smooth muscle cell interactions.

REFERENCE 7

- AN 120:265249 CA
- TI High-performance liquid chromatography-thermospray mass spectrometry of epoxy polyunsaturated fatty acids and epoxyhydroxy polyunsaturated fatty acids from an incubation mixture of rat tissue homogenate
- AU Yamane, Mototeru; Abe, Akihisa; Yamane, Sayoko
- CS Dep. Biochem., Tokyo Med. Coll., Tokyo, Japan
- SO Journal of Chromatography, B: Biomedical Sciences and Applications (1994), 652(2), 123-36
 CODEN: JCBBEP; ISSN: 1387-2273
- DT Journal
- LA English
- AB A method for the anal. of epoxy polyunsatd. fatty acids (EpPUFAs) and epoxyhydroxy polyunsatd. fatty acids (EpHPUFAs) in rat tissue homogenate, with homo- γ -linolenic acid (20:3,n-6), arachidonic acid (20:4,n-6), eicosapentaenoic acid (20:5,n-3) or docosahexaenoic acid (22:6,n-3) as a substrate, was developed. Extraction with dichloromethane at pH 4-5 and concentration

in the presence of pyridine were performed. Spectral anal. of chromatograms obtained with HPLC-thermospray mass spectrometry showed the presence of EpPUFAs, EpHPUFAs and dihydroxy metabolites (DiHPUFAs) of EpPUFAs corresponding to each precursor fatty acid. On a selected-ion monitoring chromatogram, many EpPUFAs, EpHPUFAs and DiHPUFAs in an extract from an incubation mixture of each precursor fatty acid in aged rat tissue homogenate were detected simultaneously within 70 min. EpPUFAs and DiHPUFAs derived from 20:3 (n-6) or 20:5 (n-3) were detected in significant amts. From these results, a highly active cytochrome P 450 system or nonenzymic oxidative reactions in aged rat tissue homogenate

were suggested.

REFERENCE 8

- AN 119:265901 CA
- TI Facile preparation and structural determination of monohydroxy derivatives of docosahexaenoic acid (HDoHE) by $\alpha\text{-tocopherol-directed}$ autoxidation
- AU Reynaud, Denis; Thickitt, Christopher P.; Pace-Asciak, Cecil R.
- CS Res. Inst., Hosp. Sick Child., Toronto, ON, M5G 1X8, Can.
- SO Analytical Biochemistry (1993), 214(1), 165-70 CODEN: ANBCA2; ISSN: 0003-2697
- DT Journal
- LA English
- Polyunsatd. fatty acids are oxidized through both enzymic and nonenzymic AB reactions into hydroxy derivs. With increasing interest in dietary manipulations through ingestion of the highly unsatd. fish oil fatty acids, eicosapentaenoic acid and docosahexaenoic acid (DHA), methods to measure their metabolism are required. In this study the authors report the simple and expedient α -tocopherol-directed autoxidative preparation of a series of monohydroxy derivs. of DHA to provide a relatively homogeneous hydroxylation along each of the double bonds of the fatty substrate. Products were purified by high-performance liquid chromatog. (HPLC) and their structures elucidated by the characteristic fragmentation pattern of the hydrogenated Me ester trimethylsilyl ether derivs. by gas chromatog.-mass spectrometry. Nine products were isolated in 20.2% yield overall, ranging from 1.55 to 4.14% yield of isolated compound These were identified as 7, 8, 10, 11, 13, 14, 16, 17, and 20-HDoHEs (monohydroxydocosahexaenoic acids). Two of these products (14- and 17-HDOHE) could not be separated under the HPLC conditions used but were clearly distinguished using selected ion chromatog. by their distinct mass spectral fragmentation. This method is highly suitable for the generation of stds. to investigate the metabolism of DHA in tissues.

- AN 117:187518 CA
- TI High-performance liquid chromatography-thermospray mass spectrometry of hydroperoxy polyunsaturated fatty acid acetyl derivatives
- AU Yamane, Mototeru; Abe, Akihisa; Yamane, Sayoko; Ishikawa, Fumio
- CS Dep. Biochem., Tokyo Med. Coll., Tokyo, Japan
- SO Journal of Chromatography (1992), 579(1), 25-36 CODEN: JOCRAM; ISSN: 0021-9673
- DT Journal
- LA English
- AB A method for the anal. of hydroperoxy polyunsatd. fatty acids was developed. The hydroperoxy groups were acetylated by acetic anhydride, and the mixture was partially purified on a Sep-Pak C18 cartridge and analyzed by high-performance liquid chromatog. with thermospray mass spectrometry. Generally, the base ion, [M + H n(60)] + or [M + H n(60) n(H2O)] +, is produced through elimination of acetic acid or water (n = number of hydroperoxy groups). The detection limit for these derivs. was approx. 1 pmol at concns. of hydroperoxy polyenoic acids prior to derivatization. Using this method, many hydroxy and hydroperoxy polyunsatd. fatty acid derivs. could be detected simultaneously within 30 min on a selected-ion monitoring detection chromatogram without a gradient system. The assay was successfully applied to hydroxy and hydroperoxy polyunsatd. fatty acids from an incubation mixture of rat brain homogenate to which polyunsatd. fatty acids has been added.

AN 116:211313 CA

TI Identification and egg hatching activity of monohydroxy fatty acid eicosanoids in the barnacle Balanus balanoides

AU Hill, E. M.; Holland, D. L.

CS Sch. Ocean Sci., Univ. Coll. North Wales, Anglesey, LL59 5EY, UK

Proceedings of the Royal Society of London, Series B: Biological Sciences (1992), 247(1318), 41-6
CODEN: PRLBA4; ISSN: 0080-4649

DT Journal

LA English

Monohydroxy fatty acids (MHFAs) were isolated from homogenates of the AΒ barnacle B. balanoides and identified by gas chromatog. -mass spectrometry (GC-MS) as 14- and 17-hydroxy docosahexaenoic acids, 8-, 11-, 12-, 15- and 18-hydroxy eicosapentaenoic acids, 13- and 16-hydroxyoctadecatrienoic acids, and 9-, 13- and 15-hydroxyoctadecadienoic acids. Each monohydroxy fatty acid was tested for egg hatching activity in a bioassay using Elminius modestus egg masses, but 8-hydroxy-5, 9, 11, 14, 17-eicosapentaenoic acid (8-HEPE) was the only MHFA with barnacle egg hatching activity. Studies on the egg hatching activity of MHFAs prepared from the oxidation of polyunsatd. fatty acids showed that activity was confined to the 8-hdyroxy isomer of eicosapentaenoic acid and arachidonic acid, and that unsatn. at C5 and C14, but not C17, was essential for activity. In addition, the 8(R) conformation is necessary for activity, as 8(R)-HEPE caused egg hatching at 10-7M, whereas the enantiomer 8(S)-HEPE was inactive.

L8 ANSWER 5 OF 6 REGISTRY COPYRIGHT 2004 ACS on STN

RN 90780-51-1 REGISTRY

CN 4,7,10,13,17,19-Docosahexaenoic acid, 16-hydroxy-, (4Z,7Z,10Z,13Z,17E,19Z)-(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 4,7,10,13,17,19-Docosahexaenoic acid, 16-hydroxy-, (E,Z,Z,Z,Z,Z)-

FS STEREOSEARCH

DR 131391-59-8

MF C22 H32 O3


LC STN Files: CA, CAPLUS, CHEMCATS, CSCHEM, USPATZ, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1907 TO DATE)

7 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

AN 139:79114 CA

TI Eicosapentaenoic acid and docosahexaenoic acid analogs induction of host defense against bacteria

IN Serhan, Charles N.; Colgan, Sean P.

```
The Brigham and Women's Hospital, USA
PA
     PCT Int. Appl., 65 pp.
SO
     CODEN: PIXXD2
DT
     Patent
     English
LΑ
FAN.CNT 2
                                            APPLICATION NO.
                                                              DATE
                  KIND DATE
     PATENT NO.
                                            -----
                                                               _____
     _____
                                            WO 2002-US40586 20021218
                     A2 20030703
ΡI
     WO 2003053423
                      A3 20040226
     WO 2003053423
             AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
                                                               20021218
                                             US 2002-323867
                       A1
                             20031009
     US 2003191184
                                             US 2002-323591
                                                               20021218
                             20031016
     US 2003195248
                       A1
PRAI US 2001-342138P 20011218
     Methods to cause tissue, such as mucosal cells, to express increased amts.
     of bactericidal permeability increasing protein (BPI) are described.
     Various BPI inducing agents include eicosapentaenoic acid (EPA) analogs
     and docosahexaenoic acid (DHA) analogs. Thus, 18R-EPA analogs induced the
     formation of BPI. Results demonstrated quant. PCR for BPI in epithelial
     cells.
REFERENCE 2
AN
     135:190408 CA
     Aspirin-triggered lipid mediators
TI
     Serhan, Charles N.; Clish, Clary B.
IN
     The Brigham and Women's Hospital, Inc., USA
PA
     PCT Int. Appl., 74 pp.
SO
     CODEN: PIXXD2
     Patent
DΤ
LΑ
     English
FAN.CNT 1
                       KIND DATE
                                             APPLICATION NO. DATE
     PATENT NO.
                       ----
                                             WO 2001-US5196 20010216
     WO 2001060778
                        A2
                             20010823
ΡI
     WO 2001060778
                        C2
                             20021024
                      A3
                             20030116
     WO 2001060778
              AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
              HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
              LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
              SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
              DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
              BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                             US 2001-785866
                                                               20010216
      US 2002055538
                        A1
                             20020509
     US 6670396
                        B2
                              20031230
                                             EP 2001-910912
                                                               20010216
                        A2
                              20030402
      EP 1296923
              AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                                               20010216
                                             JP 2001-559832
                        T2 20030902
      JP 2003525880
                                             US 2003-663061
                                                               20030912
      US 2004059144
                        Al
                              20040325
```

PRAI US 2000-183078P 20000216 US 2000-238814P 20001006 US 2001-785866 20010216 WO 2001-US5196 20010216

AB Aspirin triggered lipid mediators are disclosed which are useful for the treatment or prevention of inflammation associated with various diseases, including ischemia. The present invention provides that inflammatory exudates from mice treated with ω -3 PUFA and aspirin generate a novel array of bioactive lipid signals. Human endothelial cells with upregulated COX-2 treated with aspirin converted C20:5 w-3 to 18R-HEPE and 15R-HEPE. Each was used by polymorphonuclear leukocytes to generate sep. classes of novel trihydroxy-containing mediators, including 15R-lipoxin and 5,12,18R-triHEPE. These compds. were potent inhibitors of human polymorphonuclear leukocyte transendothelial migration and infiltration in vivo.

REFERENCE 3

AN 119:265901 CA

- TI Facile preparation and structural determination of monohydroxy derivatives of docosahexaenoic acid (HDoHE) by $\alpha\text{-tocopherol-directed}$ autoxidation
- AU Reynaud, Denis; Thickitt, Christopher P.; Pace-Asciak, Cecil R.
- CS Res. Inst., Hosp. Sick Child., Toronto, ON, M5G 1X8, Can.
- SO Analytical Biochemistry (1993), 214(1), 165-70 CODEN: ANBCA2; ISSN: 0003-2697
- DT Journal
- LA English
- Polyunsatd. fatty acids are oxidized through both enzymic and nonenzymic AR reactions into hydroxy derivs. With increasing interest in dietary manipulations through ingestion of the highly unsatd. fish oil fatty acids, eicosapentaenoic acid and docosahexaenoic acid (DHA), methods to measure their metabolism are required. In this study the authors report the simple and expedient α -tocopherol-directed autoxidative preparation of a series of monohydroxy derivs. of DHA to provide a relatively homogeneous hydroxylation along each of the double bonds of the fatty substrate. Products were purified by high-performance liquid chromatog. (HPLC) and their structures elucidated by the characteristic fragmentation pattern of the hydrogenated Me ester trimethylsilyl ether derivs. by gas chromatog.-mass spectrometry. Nine products were isolated in 20.2% yield overall, ranging from 1.55 to 4.14% yield of isolated compound These were identified as 7, 8, 10, 11, 13, 14, 16, 17, and 20-HDoHEs (monohydroxydocosahexaenoic acids). Two of these products (14- and 17-HDOHE) could not be separated under the HPLC conditions used but were clearly distinguished using selected ion chromatog. by their distinct mass spectral fragmentation. This method is highly suitable for the generation of stds. to investigate the metabolism of DHA in tissues.

- AN 117:187518 CA
- TI High-performance liquid chromatography-thermospray mass spectrometry of hydroperoxy polyunsaturated fatty acid acetyl derivatives
- AU Yamane, Mototeru; Abe, Akihisa; Yamane, Sayoko; Ishikawa, Fumio
- CS Dep. Biochem., Tokyo Med. Coll., Tokyo, Japan
- SO Journal of Chromatography (1992), 579(1), 25-36 CODEN: JOCRAM; ISSN: 0021-9673
- DT Journal
- LA English
- AB A method for the anal. of hydroperoxy polyunsatd. fatty acids was developed. The hydroperoxy groups were acetylated by acetic anhydride, and the mixture was partially purified on a Sep-Pak C18 cartridge and

analyzed by high-performance liquid chromatog. with thermospray mass spectrometry. Generally, the base ion, [M + H - n(60)] + or [M + H - n(60)] - n(H2O)] +, is produced through elimination of acetic acid or water (n = number of hydroperoxy groups). The detection limit for these derivs. was approx. 1 pmol at concns. of hydroperoxy polyenoic acids prior to derivatization. Using this method, many hydroxy and hydroperoxy polyunsatd. fatty acid derivs. could be detected simultaneously within 30 min on a selected-ion monitoring detection chromatogram without a gradient system. The assay was successfully applied to hydroxy and hydroperoxy polyunsatd. fatty acids from an incubation mixture of rat brain homogenate to which polyunsatd. fatty acids has been added.

REFERENCE 5

- AN 114:39806 CA
- TI Stereochemical analysis of hydroxylated docosahexaenoates produced by human platelets and rat brain homogenate
- AU Kim, H. Y.; Karanian, J. W.; Shingu, T.; Salem, N., Jr.
- CS Sect. Anal. Chem., NIAAA, Bethesda, MD, 20892, USA
- SO Prostaglandins (1990), 40(5), 473-90 CODEN: PRGLBA; ISSN: 0090-6980
- DT Journal
- LA English
- The stereochem. configuration of hydroxylated products of docosahexaenoic acid (22:6ω3) formed by human platelets and rat brain homogenate were characterized for the first time. Chiral phase HPLC was employed along with autoxidized 22:6ω3 as reference material. The 14- and 11-hydroy 22:6ω3 (HDHE) products produced by human platelets were in the S configuration. Rat brain homogenate produced all of the 10 possible positional isomers when incubated with 22:6ω3. Their retention behavior on the reversed and chiral phase HPLC columns and GC/MS/EI anal. indicated that they were 20-, 17-, 16-, 14-, 13-, 11-, 10-, 8-, 7- and 4-HDHE. However, stereochem. anal. revealed that each positional isomer was a racemic mixture, suggesting that these were not formed by lipoxygenation but mainly by peroxidn. process.

REFERENCE 6

- AN 101:35331 CA
- TI Autooxidation of docosahexaenoic acid: analysis of ten isomers of hydroxydocosahexaenoate
- AU VanRollins, Mike; Murphy, Robert C.
- CS Health Sci. Cent., Univ. Colorado, Denver, CO, 80262, USA
- SO Journal of Lipid Research (1984), 25(5), 507-17 CODEN: JLPRAW; ISSN: 0022-2275
- DT Journal
- LA English
- Docosahexaenoic acid, an n-3 essential fatty acid, is enzymically converted by platelets, basophils, and liver microsomes into metabolites containing conjugated diens with allylic hydroxyl groups. To help identify these metabolites, stds. were prepared by autoxidn. of docosahexaenoic acid. After isolation by reverse phase and normal phase high-performance chromatog. (HPLC), 10 hydroxy isomers of docosahexaenoic acid were identified by capillary gas-liquid chromatog., UV spectroscopy, and mass spectrometry. From these studies and reported elution orders for similar metabolites derived from linoleic, linolenic, and arachidonic acids, 2 basic HPLC elution patterns became apparent. Under reverse phase chromatog. conditions, the distance of the trans-double bond from the carboxyl group was the critical parameter in determining the elution order.

Under

silicic acid chromatog. conditions, the distance of the hydroxyl from the carbomethoxy group seemed to determine the elution order. The dramatic

difference in selectivity between reverse and normal phase HPLC of the hydroxy acids provides critical information useful for identifying endogenous metabolites.

REFERENCE 7

AN 101:19194 CA Oxidation of docosahexaenoic acid by rat liver microsomes TIVanRollins, Mike; Baker, Rodney C.; Sprecher, Howard W.; Murphy, Robert C. ΑU Health Sci. Cent., Univ. Colorado, Denver, CO, 80262, USA CS Journal of Biological Chemistry (1984), 259(9), 5776-83 SO CODEN: JBCHA3; ISSN: 0021-9258 DTJournal LΑ English [1-14C]docosahexaenoic acid (n-3) was incubated at 37° for 30 min AΒ

in the presence of rat liver microsomes and 1 mM NADPH. The products were isolated by using organic solvent extns., and reverse phase and normal phase HPLC. Isolates were identified by UV spectroscopy, capillary gas-liquid chromatog., and gas chromatog.-mass spectrometer. The major metabolites were: 19,20-, 16,17-, 13,14-, 10,11-, and 7,8-dihydroxydocosapentaenoic acids, 22-hydroxydocosahexaenoic acid, and 21-hydroxydocosahexaenoic acid. The minor metabolites were 17-hydroxy-4,7,10,13,15,19-, 16-hydroxy-4,7,10,17,19-, 14-hydroxy-4,7,10,12,-16,19-, 13-hydroxy-4,7,10,14,16,19-, 11-hydroxy-4,7,9,13,16,19-, 10-hydroxy-4,7,11,13,16,19-,8-hydroxy-4,6,10,13,16,19-, and 7-hydroxy-4,8,10,13,16,19-docosahexaenoic acids. These metabolites of docosahexaenoic acid resulted from 4 distinct classes of oxidation, ω -hydroxylations, $(\omega-1)$ -hydroxylations, epoxidns., and lipoxygenase-like hydroxylations. The similarity of these product profiles to those reported for comparable microsomal incubations with other essential fatty acids suggest that microsome cytochrome P 450 monooxygenases were involved.

L8 ANSWER 6 OF 6 REGISTRY COPYRIGHT 2004 ACS on STN

RN 87042-40-8 REGISTRY

CN 4,7,10,12,16,19-Docosahexaenoic acid, 14-hydroxy-, (4Z,7Z,10Z,12E,16Z,19Z)-(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 4,7,10,12,16,19-Docosahexaenoic acid, 14-hydroxy-, (E,Z,Z,Z,Z)-

FS STEREOSEARCH

DR 128302-08-9, 131485-68-2

MF C22 H32 O3

LC STN Files: BEILSTEIN*, CA, CAPLUS, CHEMCATS, CSCHEM, TOXCENTER, USPAT2, USPATFULL

(*File contains numerically searchable property data)

DT.CA CAplus document type: Conference; Journal; Patent

RL.P Roles from patents: BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process)

Double bond geometry as shown.

$$_{HO_2C}$$
 \overline{z} \overline{z} \overline{z} E $_{OH}$

```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**
```

32 REFERENCES IN FILE CA (1907 TO DATE)
32 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

```
AN
    139:79114 CA
    Eicosapentaenoic acid and docosahexaenoic acid analogs induction of host
ΤI
    defense against bacteria
    Serhan, Charles N.; Colgan, Sean P.
IN
    The Brigham and Women's Hospital, USA
PA
    PCT Int. Appl., 65 pp.
SO
    CODEN: PIXXD2
    Patent
DT
LΑ
    English
FAN.CNT 2
                                       APPLICATION NO. DATE
                KIND DATE
    PATENT NO.
                   ----
                          -----
                                        WO 2002-US40586 20021218
    WO 2003053423
                    A2
                           20030703
PΙ
                    A3
                          20040226
    WO 2003053423
```

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003191184 A1 20031009 US 2002-323867 20021218 US 2003195248 A1 20031016 US 2002-323591 20021218

PRAI US 2001-342138P 20011218

AB Methods to cause tissue, such as mucosal cells, to express increased amts. of bactericidal permeability increasing protein (BPI) are described. Various BPI inducing agents include eicosapentaenoic acid (EPA) analogs and docosahexaenoic acid (DHA) analogs. Thus, 18R-EPA analogs induced the formation of BPI. Results demonstrated quant. PCR for BPI in epithelial cells.

- AN 136:147175 CA
- TI Monohydroxylated fatty acid content in peripheral blood mononuclear cells and immune status of people at long times after the Chernobyl accident
- AU Chumak, Anatoliy; Thevenon, Chantal; Gulaya, Nadya; Guichardant, Michel; Margitich, Victor; Bazyka, Dimitry; Kovalenko, Alexander; Lagarde, Michel; Prigent, Annie-France
- CS INSERM, Biochimie et Pharmacologie INSA Lyon, Villeurbanne, 69621, Fr.
- SO Radiation Research (2001), 156(5, Pt. 1), 476-487 CODEN: RAREAE; ISSN: 0033-7587
- PB Radiation Research Society
- DT Journal
- LA English
- The monohydroxylated fatty acid content of peripheral blood mononuclear cells from 23 cleanup workers and 16 unexposed individuals was studied in relation to their immune status after the Chernobyl accident. Men with absorbed doses below 0.32 Gy showed higher levels of free and esterified 12-hydroxyeicosatetraenoic acid (12-HETE) than unexposed men, whereas 15-HETE and the 17-hydroxy derivative of C22 fatty acid (17-OH 22), either

free or esterified in phospholipids, were increased in a dose-dependent manner. The percentage of CD4-pos. cells was also increased significantly in heavily irradiated men, whereas the percentage of CD8-pos. cells tended to decrease with dose. Furthermore, the absolute count of CD4-pos. cells was correlated pos. with the amount of esterified 15-HETE in the phospholipid fraction of the mononuclear cells and with the total 15-HETE. These results show for the first time that the accumulation of autoxidized/lipoxygenase products of polyunsatd. fatty acids in the mononuclear cells of irradiated individuals was associated with immune imbalance. This may be the basis for certain late effects of radiation such as autoimmune disorders, somatic and neoplastic diseases, and early aging.

RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

REFERENCE 3

135:190408 CA

AN

```
Aspirin-triggered lipid mediators
TI
     Serhan, Charles N.; Clish, Clary B.
IN
PA
     The Brigham and Women's Hospital, Inc., USA
     PCT Int. Appl., 74 pp.
SO
     CODEN: PIXXD2
DT
     Patent
LA
     English
FAN.CNT 1
                                                APPLICATION NO. DATE
     PATENT NO.
                    KIND DATE
                         ----
                                -----
                                20010823
                                                  WO 2001-US5196
     WO 2001060778
                          A2
                                                                      20010216
PΙ
     WO 2001060778
                          C2
                                20021024
     WO 2001060778 A3
                                20030116
              AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
               CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
               HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
               LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
               SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
          ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                                 US 2001-785866
     US 2002055538
                          A1
                                20020509
                                                                      20010216
     US 6670396
                          B2
                                 20031230
                                                  EP 2001-910912
     EP 1296923
                          A2
                                20030402
                                                                      20010216
              AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2003525880
                          T2
                                 20030902
                                                 JP 2001-559832
                                                                      20010216
     US 2004059144
                          A1
                                 20040325
                                                  US 2003-663061
                                                                      20030912
PRAI US 2000-183078P
                         20000216
     US 2000-238814P
                         20001006
     US 2001-785866
                         20010216
     WO 2001-US5196
                         20010216
```

Aspirin triggered lipid mediators are disclosed which are useful for the treatment or prevention of inflammation associated with various diseases, including ischemia. The present invention provides that inflammatory exudates from mice treated with ω-3 PUFA and aspirin generate a novel array of bioactive lipid signals. Human endothelial cells with upregulated COX-2 treated with aspirin converted C20:5 w-3 to 18R-HEPE and 15R-HEPE. Each was used by polymorphonuclear leukocytes to generate sep. classes of novel trihydroxy-containing mediators, including 15R-lipoxin and 5,12,18R-triHEPE. These compds. were potent inhibitors of human polymorphonuclear leukocyte transendothelial migration and infiltration in vivo.

REFERENCE 4

AN 129:202364 CA

TI N-3 fatty acid deficiency in the rat pineal gland: effects on phospholipid molecular species composition and endogenous levels of melatonin and lipoxygenase products

AU Zhang, Hongjian; Hamilton, Jillonne H.; Salem, Norman, Jr.; Kim, Hee-Yong

CS Section of Mass Spectrometry, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD, 20852, USA

SO Journal of Lipid Research (1998), 39(7), 1397-1403 CODEN: JLPRAW; ISSN: 0022-2275

PB Lipid Research, Inc.

DT Journal

LA English

N-3 essential fatty acid deficiency affects a number of biol. and physiol. AB processes. In this study, the authors investigated the effect of n-3 essential fatty acid status on two key pineal biochem. functions, melatonin production and lipoxygenation, using pineal glands from rats given an n-3-adequate or n-3-deficient diet. The pineal total lipid profile and phospholipid mol. species distribution altered by n-3 deficiency were evaluated in parallel. In pineal glands from n-3-deficient rats, an 87% reduction of 22:6n-3 (docosahexaenoic acid) was observed, and this decrease was accompanied by increases in 22:4n-6 (docosatetraenoic acid, 3-fold), 22:5n-6 (docosapentaenoic acid, 12-fold), and 20:4n-6 (arachidonic acid, 48%). The significant decrease of 22:6n-3 containing species in phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylserine (PS) was also evident. These decreases in 22:6n-3 containing PL species were compensated by substantial accumulations of 22:4n-6 or 22:5n-6 and slight increases in 20:4n-6 containing PL species in PC and PE. In PS, however, the accumulation of n-6 species was not adequate to compensate for the loss of 22:6n-3 species. N-3 deficiency significantly reduced non-esterified 20:4n-6 and 22:6n-3 levels in pineals (25% and 65%, resp.). Concomitantly, the endogenous 12-HETE level decreased by 35% in deficient pineals. In contrast, n-3 deficiency led to a more than 60% increase in the daytime pineal melatonin level. In conclusion, n-3 fatty acid deficiency not only has profound effects on pineal lipid profiles but also on pineal biochem. activities. These results suggest that n-3 fatty acids may play a critical role in regulating pineal function.

RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

REFERENCE 5

AN 124:227170 CA

TI Production of monohydroxy derivatives from highly unsaturated fatty acids in the gills of red sea bream Pagrus major

AU Iijima, Noriaki; Hada, Takahiko; Kayama, Mitsu

CS Faculty of Applied Biological Science, Hiroshima Univ., Hiroshima, 739, Japan

SO Fisheries Science (1996), 62(1), 114-21 CODEN: FSCIEH; ISSN: 0919-9268

PB Japanese Society of Fisheries Science

DT Journal

LA English

AB 12-Hydroxyeicosatetraenoic acid and 15-hydroxyeicosatetraenoic acid were produced as major and minor monohydroxylated products in a microsome fraction, when [1-14C]arachidonic acid was incubated with the microsome or cytosol fraction prepared from frozen stored gill tissue of red sea bream P. major. The endogeneous products extracted from the microsome fraction of the red sea bream gill were isolated by HPLC and identified as 12-hydroxyeicosatetraenoic acid, 12-hydroxyeicosapentaenoic acid, and

14-hydroxydocosahexaenoic acid by UV absorption spectrometry and gas chromatog.-mass spectrometry. These data suggest that arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid are converted to their monohydroxy derivs. via the hydroperoxides by the action of 12-lipoxygenase-like enzyme, which is distributed in the microsomes of red sea bream gill.

REFERENCE 6

- AN 124:26230 CA
- TI Biosynthesis of docosanoids by human platelet: Cardiovascular properties
- AU Karanian, John W.; Kim, Hee Yong; Salem, Norman Jr.
- CS Laboratory Membrane Biochemistry and Biophysics, DICBR/NIAAA, Rockville, MD, 20852, USA
- Cardiovascular Disease 2: Cellular and Molecular Mechanisms, Prevention, and Treatment, [Proceedings of the Washington International Spring Symposium], 14th, Washington, D. C., June 6-10, 1994 (1995), Meeting Date 1994, 269-77. Editor(s): Gallo, Linda L. Publisher: Plenum, New York, N. Y.
 - CODEN: 61ZNA9
- DT Conference
- LA English
- AB A reliable purification and quantification method is presented that was used to characterize the metabolism and production of the hydroxylated derivs. of
- 22:5n3,
 22:6n3, 22:5n5 and 22:5n6 from mammalian platelets. Their biol.
 properties in platelet and vascular smooth muscle cell function is
 discussed.

- AN 122:311127 CA
- TI Eicosanoid generating capacities of different tissues from the rainbow trout, Oncorhynchus mykiss
- AU Knight, John; Holland, Jason W.; Bowden, Linda A.; Halliday, Katrina; Rowley, Andrew F.
- CS School Biological Sciences, University Wales, Swansea, Singleton Park, SA2 8PP, UK
- SO Lipids (1995), 30(5), 451-8 CODEN: LPDSAP; ISSN: 0024-4201
- PB AOCS Press
- DT Journal
- LA English
- The eicosanoid-generating potential of the brain, gills, skin, ovary, AR muscle, eye, liver, spleen, heart, and alimentary canal in the rainbow trout, O. mykiss, was examined All the organs/tissues examined synthesized the 12-lipoxygenase products, 12-hydroxyeicosatetraenoic acid (12-HETE), and 12-hydroxyeicosapentaenoic acid (12-HEPE), implying the widespread nature of this enzyme in trout. Both prostaglandin E and LTC were also found in variable amts. in the organs, with the greatest amount of PGE found in the gill. Leukotriene (LT) B4 and LTB5 were found in supernatants from Ca2+ ionophore-challenged brain, skin, ovary, liver, spleen, and heart, but the lipoxins A4 and A5 were only present in brain, ovary, and spleen in relatively small amts. As lipoxins have previously been shown to be synthesized by macrophages in rainbow trout, and related cells (microglial cells) are found in the brain of mammals, the localization of macrophage-like cells in trout brain was investigated immunocytochem. Monoclonal antibodies specific for trout leukocytes failed to identify any microglial-like cells in sections of the brain, although microvessels containing immuno-pos. reaction products were observed A number of distinct lipoxygenase products were found in supernatants of ionophore-challenged gill, including 14-hydroxydocosahexaenoic acid, 12-HETE, and 12-HEPE, and

a large number of dihydroxy fatty acid derivs. with conjugated triene chromophores. One of these products was tentatively identified as 8(R),15(S)-dihydroxyeicosatetraenoic acid, a dual 12- and 15-lipoxygenase product, but apparently no LTB4 was generated by this tissue.

REFERENCE 8

- AN 121:277471 CA
- TI Inhibitory effects of n-6 and n-3 hydroxy fatty acids on thromboxane (U46619)-induced smooth muscle contraction
- AU Karanian, J. W.; Kim, H. Y.; Salem, Norman, Jr.
- CS Lab. Membrane Biochem. and Biophysics, Natl. Inst. Alcohol Abuse and Alcoholism, Bethesda, MD, USA
- Journal of Pharmacology and Experimental Therapeutics (1994), 270(3), 1105-9
 CODEN: JPETAB; ISSN: 0022-3565
- DT Journal
- LA English
- Mammalian platelets are capable of enzymically producing a number of n-6 and n-3 hydroxy fatty acids. Human platelet suspensions produce two major docosahexaenoic acid (22:6n3) metabolites, namely, 11-OH- and 14-OH-22:6n3. The hydroxy fatty acids which were formed by human platelets and purified by high performance liquid chromatog. specifically antagonize the contractile effects of a thromboxane mimetic, U46619, in airway, visceral and, especially, in the vascular smooth muscle prepns.
- studied.

The efficacy of OH-22:6n3 (IC25 = 1.1 μ M) was compared to other n-6 and n-3 hydroxy fatty acids in the rat aortic ring preparation. The OH-22:6n3 was significantly more potent with the exception of OH-22:5n3. The rank order of their potency was 14-OH-22:5n3 \geq 14-OH-22:6n3 \rangle 17-OH-22:6n3 \geq 11-OH-22:5n3 \rangle 12-OH-20:5n3 \rangle 12-OH-20:4n6 \rangle 14-OH-22:5n6 \rangle 13-OH-18:2n6 \rangle 14-OH-22:5n5. Antagonism of thromboxane effects may be an important aspect of the biol. function of 22-carbon n-3 hydroxylated fatty acids in the platelet-vascular smooth muscle cell interactions.

REFERENCE 9

- AN 121:73909 CA
- TI Antipsychotics containing docosahexaenoic acid or its derivatives
- IN Nishikawa, Masazumi; Kimura, Seiji
- PA Maruha Kk, Japan
- SO Jpn. Kokai Tokkyo Koho, 5 pp. CODEN: JKXXAF
- DT Patent
- LA Japanese
- FAN CNT 1

PAN.CIVI I			
PATENT NO.	KIND DATE	APPLICATION NO.	DATE
PI JP 06072868	A2 19940315	JP 1992-227510	19920826
US 6306907	B1 20011023	US 1993-111831	19930825
PRAI JP 1992-227510	19920826		

Antipsychotics contain ≥1 compds. chosen from docosahexaenoic acid
(I) or its derivs. as active ingredients, which show high safety and are useful for prevention and treatment of psychosis. I at 30 μM reduced N-methyl-D-aspartic acid receptor antagonism of phencyclidine in hippocampus CA1 region nerve cell sample of sliced rat brain. Et docosahexaenoate at 300 mg 3 times a day improved neg. symptoms in schizophrenia patients and showed no side effects.

AN 120:265249 CA

- High-performance liquid chromatography-thermospray mass spectrometry of epoxy polyunsaturated fatty acids and epoxyhydroxy polyunsaturated fatty acids from an incubation mixture of rat tissue homogenate
- AU Yamane, Mototeru; Abe, Akihisa; Yamane, Sayoko

CS Dep. Biochem., Tokyo Med. Coll., Tokyo, Japan

- SO Journal of Chromatography, B: Biomedical Sciences and Applications (1994), 652(2), 123-36 CODEN: JCBBEP; ISSN: 1387-2273
- DT Journal
- LA English

AB A method for the anal. of epoxy polyunsatd. fatty acids (EpPUFAs) and epoxyhydroxy polyunsatd. fatty acids (EpHPUFAs) in rat tissue homogenate, with homo- γ -linolenic acid (20:3,n-6), arachidonic acid (20:4,n-6), eicosapentaenoic acid (20:5,n-3) or docosahexaenoic acid (22:6,n-3) as a substrate, was developed. Extraction with dichloromethane at pH 4-5 and concentration

in the presence of pyridine were performed. Spectral anal. of chromatograms obtained with HPLC-thermospray mass spectrometry showed the presence of EpPUFAs, EpHPUFAs and dihydroxy metabolites (DiHPUFAs) of EpPUFAs corresponding to each precursor fatty acid. On a selected-ion monitoring chromatogram, many EpPUFAs, EpHPUFAs and DiHPUFAs in an extract from an incubation mixture of each precursor fatty acid in aged rat tissue homogenate were detected simultaneously within 70 min. EpPUFAs and DiHPUFAs derived from 20:3 (n-6) or 20:5 (n-3) were detected in significant amts. From these results, a highly active cytochrome P 450 system or nonenzymic oxidative reactions in aged rat tissue homogenate were suggested.

=> file ca COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	30.60	30.81
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.96	-3.96

FILE 'CA' ENTERED AT 11:54:16 ON 27 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Sep 2004 VOL 141 ISS 14 FILE LAST UPDATED: 23 Sep 2004 (20040923/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 18

L9 36 L8

L10 2 L9 AND INFLAMMATION

=> d 1-2 l10 bib abs

L10 ANSWER 1 OF 2 CA COPYRIGHT 2004 ACS on STN

AN 139:177077 CA

TI Novel Docosatrienes and 17S-Resolvins Generated from Docosahexaenoic Acid in Murine Brain, Human Blood, and Glial Cells

AU Hong, Song; Gronert, Karsten; Devchand, Pallavi R.; Moussignac, Rose-Laure; Serhan, Charles N.

CS Perioperative and Pain Medicine, Department of Anesthesiology, Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA

SO Journal of Biological Chemistry (2003), 278(17), 14677-14687 CODEN: JBCHA3; ISSN: 0021-9258

PB American Society for Biochemistry and Molecular Biology

DT Journal

LA English

Docosahexaenoic acid (DHA, C22:6) is highly enriched in brain, synapses, ΑB and retina and is a major ω -3 fatty acid. Deficiencies in this essential fatty acid are reportedly associated with neuronal function, cancer, and inflammation. Here, using new lipid analyses employing high performance liquid chromatog. coupled with a photodiode-array detector and a tandem mass spectrometer, a novel series of endogenous mediators was identified in blood, leukocytes, brain, and glial cells as 17S-hydroxy-containing docosanoids denoted as docosatrienes (the main bioactive member of the series was 10,17S-docosatriene) and 17S series resolvins. These novel mediators were biosynthesized via epoxide-containing intermediates and proved potent (pico- to nanomolar range) regulators of both leukocytes reducing infiltration in vivo and glial cells blocking their cytokine production These results indicate that DHA is the precursor to potent protective mediators generated via enzymic oxygenations to novel docosatrienes and 17S series resolvins that each regulate events of interest in inflammation and resolution

RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 2 CA COPYRIGHT 2004 ACS on STN

AN 135:190408 CA

TI Aspirin-triggered lipid mediators

IN Serhan, Charles N.; Clish, Clary B.

PA The Brigham and Women's Hospital, Inc., USA

SO PCT Int. Appl., 74 pp. CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.						KIN)	DATE			APPL:	[CAT]	DATE					
PΤ	WO.	2001	0607	 78		A2	-	2001	0823	1	WO 2	001-T	JS519	- <i></i> 96		20	00102	216
	WO	2001	0607	78		C2		2002										
	WO	NO 2001060778 W: AE, AG, AL,		A3 AM	ΔТ.	2003 AU.		BA.	BB.	BG,	BR,	BY,	BZ,	CA,	CH,	CN,		
			CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,
			HU,	ID,	IL,	IN,	IS,	JΡ, MK,	KE,	KG, mw	KP,	KR, MZ	KZ,	LC,	LK,	ĿК, PT.	RO.	RU,
			SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TR,	TT,	TZ,	UA,	ŪĠ,	ŪΖ,	VN,	YU,

```
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                20020509
                                            US 2001-785866
    US 2002055538
                          Α1
                                                                    20010216
                                20031230
    US 6670396
                          B2
                                20030402
                                            EP 2001-910912
    EP 1296923
                          Α2
                                                                    20010216
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                            JP 2001-559832
     JP 2003525880
                         T2
                                20030902
                                                                    20010216
                                            US 2003-663061
    US 2004059144
                          A1
                                20040325
                                                                    20030912
                                20000216
PRAI US 2000-183078P
                          Ρ
    US 2000-238814P
                          Р
                                20001006
    US 2001-785866
                          А3
                                20010216
    WO 2001-US5196
                          W
                                20010216
os
    MARPAT 135:190408
```

Aspirin triggered lipid mediators are disclosed which are useful for the treatment or prevention of **inflammation** associated with various diseases, including ischemia. The present invention provides that inflammatory exudates from mice treated with ω-3 PUFA and aspirin generate a novel array of bioactive lipid signals. Human endothelial cells with upregulated COX-2 treated with aspirin converted C20:5 w-3 to 18R-HEPE and 15R-HEPE. Each was used by polymorphonuclear leukocytes to generate sep. classes of novel trihydroxy-containing mediators, including 15R-lipoxin and 5,12,18R-triHEPE. These compds. were potent inhibitors of human polymorphonuclear leukocyte transendothelial migration and infiltration in vivo.